Goldman Sachs Maintains Neutral on Chemours, Lowers Price Target to $21

Benzinga · 01/07 14:19
Goldman Sachs analyst Duffy Fischer maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $24 to $21.